Litigation Details for Indivior v. Actavis Laboratories UT (D. Utah 2018)
✉ Email this page to a colleague
Indivior v. Actavis Laboratories UT (D. Utah 2018)
| Docket | ⤷ Try a Trial | Date Filed | 2018-02-06 |
| Court | District Court, D. Utah | Date Terminated | 2018-05-03 |
| Cause | 35:0271 Patent Infringement | Assigned To | Dustin B. Pead |
| Jury Demand | None | Referred To | |
| Parties | AQUESTIVE THERAPEUTICS | ||
| Patents | 9,687,454; 9,855,221 | ||
| Attorneys | Michael A. Gehret | ||
| Firms | Snell & Wilmer LLP | ||
| Link to Docket | External link to docket | ||
Small Molecule Drugs cited in Indivior v. Actavis Laboratories UT
The small molecule drugs covered by the patents cited in this case are ⤷ Try a Trial and ⤷ Try a Trial .
Details for Indivior v. Actavis Laboratories UT (D. Utah 2018)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 2018-02-06 | 2 | The patent at issue in C.A. 2:17-cv-01034 includes U.S. Patent. No. 9,687,454 (“the ’454 patent”). …expiration of United States Patent No. 9,855,221 (“the ’221 patent” or “the patent-in-suit”). …is an action for patent infringement arising under the Food and Drug Laws and Patent Laws of the United… of the ’221 patent, and Plaintiff Indivior is an exclusive licensee of the ’221 patent and holds the…expiration of the ’221 patent, Actavis has committed an act of infringement of the ’221 patent under 35 U.S.C | External link to document | |
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
